Linda Holtzman
Research Subjects
Research Interests
Linda Holtzman has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amie Scott
Pfizer Inc., New York, USA
1 shared publication - Fadi Manuel
AESARA Inc., Chapel Hill, NC 27515, USA
1 shared publication - Florin Draica
US Medical Affairs, Pfizer Inc., New York, NY 10001, USA
1 shared publication - Joanna Atkinson
Global Medical Affairs, Pfizer Ltd., Tadworth KT20 7NY, UK
1 shared publication - Maya Reimbaeva
Pfizer Inc., New York, New York
1 shared publication - Richard H. Stanford
AESARA Inc., Chapel Hill, NC 27515, USA
1 shared publication
Latest Publications
- Open Access
Comprehensive Code List Associated with Underlying Medical Conditions Identified by the CDC as High-Risk Factors for Progression to Severe COVID-19 Outcomes
A list of diagnosis codes mapped to CDC-defined high-risk conditions for severe COVID-19 outcomes is currently not available in the literature. We reviewed the CDC list of underlying conditions associated with severe COVID-19 and a coding expert and two clinicians mapped the relevant high-risk conditions to the appropriate ICD-10-CM codes. We additionally assessed the prevalence of these conditions in the Optum de-identified-Clinformatics® Data Mart Database and the Optum de-identified Electronic Health Record dataset. A comprehensive list of approximately 8200 codes were mapped to the CDC-defined high-risk underlying conditions; these ICD-10-CM codes were stratified into three groups corresponding with the CDC strength of evidence category (conclusive, suggestive, or mixed evidence). Applying these codes to administrative claims and EHR datasets demonstrated a consistent prevalence of high-risk conditions over four years (2018–2021). These findings present a comprehensive list of codes that can be used by clinicians and researchers to identify and characterize patients at high risk for severe COVID-19 outcomes.
Open AccessComprehensive Code List Associated with Underlying Medical Conditions Identified by the CDC as High-Risk Factors for Progression to Severe COVID-19 Outcomes
A list of diagnosis codes mapped to CDC-defined high-risk conditions for severe COVID-19 outcomes is currently not available in the literature. We reviewed the CDC list of underlying conditions associated with severe COVID-19 and a coding expert and two clinicians mapped the relevant high-risk conditions to the appropriate ICD-10-CM codes. We additionally assessed the prevalence of these conditions in the Optum de-identified-Clinformatics® Data Mart Database and the Optum de-identified Electronic Health Record dataset. A comprehensive list of approximately 8200 codes were mapped to the CDC-defined high-risk underlying conditions; these ICD-10-CM codes were stratified into three groups corresponding with the CDC strength of evidence category (conclusive, suggestive, or mixed evidence). Applying these codes to administrative claims and EHR datasets demonstrated a consistent prevalence of high-risk conditions over four years (2018–2021). These findings present a comprehensive list of codes that can be used by clinicians and researchers to identify and characterize patients at high risk for severe COVID-19 outcomes.